Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't see any material events that would encourage investors to be bullish enough on $MACK to keep this over $1.
sentiment: antidepressants for all
(recommendation Zoloft, Manufacturer Pfizer Inc. $PFE $32.92 +$.34)
Common stock, $0.01 par value: 200,000 shares authorized at March 31, 2017 and December 31, 2016; 131,911 and 130,197 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively
I picked this up yesterday. The chart denotes that a bounce is coming soon
Fingers crossed that the "Outlook" conclusion works out over the next few months.
https://finance.yahoo.com/news/why-merrimack-mack-down-57-082408446.html?.tsrc=rss
To be clear, they filed an extension to a CT order from 2014 on a registration from 2011. They're only extending something that was due to expire on June 8 of this year. Should not have any material affect the current beatdown their stock getting.
Some decent activity here in the AH. Check out that tape. One to watch tomorrow for sure!
Well...let me just say this...they expanded their management team and then filed a CT order. You got a couple dots to connect!
$MACK
When will this pig stop falling? Good Lord
Looks like the bottom is in for Mack. Will drift until news sends it higher.
Looks like we may have found bottom here!
$MACK Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and El...
Source: PR Newswire (US)
CAMBRIDGE, Mass., June 8, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the expansion of its senior management team through the addition of two new executive hires. Sergio L. Santillana, M.D., MSc, a medical oncologist with extensive industry experience leading a wide range of clinical development programs, has been appointed to the role of Chief Medical Officer, effective June 12, 2017. In addition, Ellen K. Forest, who served most recently as Director of Human Resources at Baxalta, has joined Merrimack to lead its talent and recruitment strategy as the new Head of Human Resources.
Merrimack Pharmaceuticals Logo (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)
"We are pleased to welcome Sergio and Ellen to Merrimack to help lead our organization in the execution of our refocused research and clinical development strategy," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer. "The collective expertise of our expanded management team is an invaluable asset to Merrimack as we focus on pinpoint execution across three wholly-owned, innovative and promising clinical-stage programs. With funding into the second half of 2019 to support our corporate objectives, a refined strategic focus and experienced teams in place to execute, we are poised to deliver on the long-term potential of our pipeline for cancer patients and our shareholders."
Sergio L. Santillana, M.D., MSc, previously served as Chief Medical Officer at ARIAD Pharmaceuticals, a commercial-stage biotechnology company acquired by Takeda Pharmaceuticals earlier this year. Prior to joining ARIAD, Dr. Santillana served in various oncology clinical development leadership roles at Takeda, GlaxoSmithKline and Eli Lilly. Before entering the biopharma industry, Dr. Santillana was a practicing board-certified medical oncologist for 15 years, including tenure at the National Cancer Institute of Peru (INEN). Dr. Santillana holds an M.S. in Experimental Therapeutics from Kellogg College at the University of Oxford and an M.D. and B.S. from the Universidad Nacional Federico Villarreal School of Medicine.
Ellen K. Forest served as Director of Human Resources at Baxalta, a global biopharmaceutical company and spin-off of Baxter International, until the company was acquired by Shire in 2016. Previously, Ms. Forest held leadership positions in Human Resources at Partners HealthCare System, the hospital system affiliated with Harvard Medical School; Dovetail Health, a home healthcare company; and TA Associates, a global private equity firm. Ms. Forest holds an M.S. in Human Resources Management and a B.S. from Emmanuel College.
About Merrimack
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on the deep understanding of cancer pathways and biological markers. All of Merrimack's product candidates, including three in clinical studies and several others in preclinical development, fit into its strategy of 1) understanding the biological problems it is trying to solve, 2) designing specific solutions and 3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. For more information, please visit Merrimack's website at www.merrimack.com.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
Contact:
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merrimack-announces-expansion-of-senior-management-team-with-appointment-of-sergio-santillana-as-chief-medical-officer-and-ellen-forest-as-head-of-human-resources-300470648.html
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright 2017 PR Newswire
$MACK seems to be in a free fall. :(
Just lowered my bid another dime.
I added down here as well
Added 50,000 shares at $1.37
I am going to reload big tomorrow and let's see if we can move it back up or not. I will give it another try tomorrow
* * $MACK Video Chart 06-05-17 * *
Link to Video - click here to watch the technical chart video
Why's the heavy shorting still going on? What are they trying to do, get this company thrown off the NASDAQ and onto the OTC?
There's much more $$ to be made with some strategic run-ups.
* * $MACK Video Chart 06-02-17 * *
Link to Video - click here to watch the technical chart video
Selling / volume is contracting here so look for the new 52-week low set earlier today to serve as your bottom. Still needs confirming, but you already have a volume confirmation.
Chart looks perfectly ugly here...and I'm thinking if they could pay out a divi at &2 and change, they must have some funds no?
Exactly 50% haircut on the week at current pps.
$MACK
$MACK As Merrimack shares hit new low, CEO vows to stay the course
http://www.bizjournals.com/boston/news/2017/05/31/as-merrimack-shares-hit-new-low-ceo-vows-to-stay.html
As Merrimack Pharmaceuticals shares hit new low, CEO vows to ...
Boston Business Journal - 1d ago
From my perspective, I'm really looking long-term here,” CEO Richard Peters said in an interview after the company's stock price fell below $2 for the first time ...
Thanks for the chart Clay
* * $MACK Video Chart 06-01-17 * *
Link to Video - click here to watch the technical chart video
It doesn't appear to have a bottom.......
Without any positive news I think it will continue to squeeze longs. The divvy payout was kind of a lure for flippers imo.
Yesterdays fall didn't finish off the $MACK cat?
$1.50 is coming soon
After the breakthrough discovery, all cancer related drugs are on the same boat to change their strategy. It does not make sense to compare drugs after the news. Rather the next 2-3 years will see a new transformation in all cancer related drugs !!!
$MACK Thanks for the chart and hope $1.80 will be bottom and I will adding more now at $1.80 to support it
I added more on the market close as well. I think $1.80 is a great support level here and move up from there
Go $MACK
Thanks Clay. Got some $1.81's at the close. Plus I saw the ask thinning. Hopefully the bottom is in.
* * $MACK Video Chart 05-31-17 * *
Link to Video - click here to watch the technical chart video
$MACK more buying compare with selling today. I like the accumulate at the dip
https://ih.advfn.com/stock-market/NASDAQ/merrimack-pharmaceuticals-inc-mm-MACK/trades
Thinking of a hard dead cat bounce after the $MACK mega-dividend wave-riders sell off and run for the hills.
Followers
|
51
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
894
|
Created
|
03/29/12
|
Type
|
Free
|
Moderators |
Robert J. Mulroy has served as our President and Chief Executive Officer and a member of our board of directors since May 1999. Prior to joining us, Mr. Mulroy worked as a management consultant in the pharmaceutical and healthcare industries. Mr. Mulroy has also worked as a consultant in the field of international development and has served as an advisor to multiple start-up companies in the biotechnology industry. Mr. Mulroy holds a master’s degree in public and private management from Yale University and a BA from Stanford University.
Yasir B. Al-Wakeel, BM BCh, has served as our Chief Financial Officer and Head of Corporate Development since August 2015. Dr. Al-Wakeel previously served in various capacities at Credit Suisse, an investment bank, from January 2008 to June 2015. While at Credit Suisse, Dr. Al-Wakeel was most recently a Director of Healthcare Investment Banking focused on biotechnology and, prior to that role, he was an Equity Research Analyst covering the biotechnology and specialty pharmaceuticals sectors. Before joining Credit Suisse, Dr. Al-Wakeel was a practicing physician, holding both clinical and academic medical posts. Dr. Al-Wakeel holds a BM BCh (Doctor of Medicine) from Oxford University, an MA in theology from Cambridge University and a BA from Cambridge University.
Peter N. Laivins has served as our Head of Development since May 2014. Mr. Laivins served as our Vice President of Clinical Development from October 2011 to May 2014. Previously, Mr. Laivins ran an independent consulting practice specializing in oncology and neuroscience from January 2010 to October 2011. Prior to that, Mr. Laivins served as Vice President of Strategic Marketing at Elan Corporation, plc, a biopharmaceutical company, from 2006 to January 2010. Mr. Laivins began his career at Pfizer Canada, joined Pfizer International in New York in 1995 and held positions of increasing responsibility at Pfizer Inc., culminating as Group Leader of Pfizer US Oncology Marketing until 2006. Mr. Laivins holds an MBA and a BS from McGill University.
Gavin MacBeath, PhD, is a founder of Merrimack and Head of Translational Medicine. Dr. MacBeath leads translational research and drives our innovative diagnostic programs, helping to ensure we get the right drug to the right patient at the right time. He is also a founder of Chestnut Pharmaceuticals, serves on the Scientific Advisory Board of Aushon Biosciences and is a Lecturer and Principal Investigator at Harvard Medical School. He joined Merrimack in 2009 after serving on the faculty in the Department of Chemistry and Chemical Biology at Harvard University for eight years where he focused on developing and applying protein microarray technology to facilitate basic research in the area of systems biology. Dr. MacBeath holds a Bachelors of Science from University of Manitoba, Canada, and a PhD in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California.
William M. McClements has served as our Head of Corporate Operations since September 2011. Previously, Mr. McClements served as Chief Human Resources Officer of Integreon Managed Solutions, Inc., a global research and business services company, from May 2010 to September 2011. Prior to that, Mr. McClements served as Chief Operating Officer and a partner at Monitor Group, a global strategic advisory firm, where he worked from 1987 to May 2010. From September 2009 to March 2010, Mr. McClements also served as Acting President of Be the Change, Inc., a nonprofit focused on creating national issue-based campaigns. Mr. McClements holds an MBA from Harvard Business School and a BA from Williams College.
Birgit M. Schoeberl, PhD, has served as our Head of Discovery since January 2015. Dr. Schoeberl served as our Senior Vice President of Research from January 2014 to January 2015, as our Vice President of Research from October 2009 to January 2014 and in various other research roles since she joined us in 2003. Prior to joining us, Dr. Schoeberl was a post-doctoral fellow at the Massachusetts Institute of Technology, where she built some of the earliest computational models of signaling networks. Dr. Schoeberl holds a PhD in systems biology from the Max Planck Institute for Dynamics of Complex Technical Systems in Germany and an MS in chemical engineering from the University of Karlsruhe in Germany.
Edward J. Stewart has served as our Head of Commercial since December 2011. Mr. Stewart served as our Senior Vice President of Business Development from March 2009 to December 2011 and in various other business development roles since he joined us in 2001. Mr. Stewart began his career at KPMG Peat Marwick LLP in the life sciences strategy consulting group. Mr. Stewart holds an MBA from the Johnson Graduate School of Management at Cornell University and a BS from Bates College.
William A. Sullivan has served as our Head of Finance and Accounting since August 2015 and our Treasurer since February 2010. Mr. Sullivan served as our Chief Financial Officer from May 2011 to August 2015, as our Vice President of Finance from February 2010 to May 2011, and as our Controller from November 2007 to February 2010. Previously, Mr. Sullivan served as Corporate Controller of Vette Corp., a thermal management solutions company, from 2004 to 2007. Mr. Sullivan began his career at Arthur Andersen LLP, where he obtained his certified public accountant license. Mr. Sullivan holds an MBA and an MS in accounting from Northeastern University’s Graduate School of Professional Accounting and a BA from Williams College.
One Kendall Square
Building 700, Suite B7201
Cambridge, MA 02139
Phone: 617-441-1000
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |